Turnaround for Novo Nordisk? Eli Lilly's Weakness plays into the cards!
Oral weight-loss pills will revolutionize the market!
Now is the moment for contrarian investors!
Reading Time: 1 minute
The newly introduced oral weight-loss pill from Eli Lilly shows a significantly lower effectiveness in the current study, with a 12.4% weight loss, compared to Novo Nordisk's high-dose oral semaglutide, which achieves over 15%. This means Lilly not only misses expectations – Novo simultaneously confirms its leading role in the emerging oral GLP-1 market. I am convinced that oral GLP-1 preparations will sell better in the long term than injections: they are easier to use, more practical for everyday life, and attractive to a broader target audience...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
